Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL
Cutaneous T-cell Lymphoma, Mycosis Fungoides, Sezary Syndrome
About this trial
This is an interventional treatment trial for Cutaneous T-cell Lymphoma focused on measuring Cutaneous T-cell Lymphoma, CTCL, Mycosis Fungoides, Sezary Syndrome, Bexarotene, Targretin, Rosiglitazone, Avandia
Eligibility Criteria
Inclusion Criteria: Patients with biopsy proven persistent or recurrent cutaneous cell lymphoma (CTCL) Stage IA-IVA Patients with a pathologic proven diagnosis of CTCL that is documented in the patient history. Patient has preserved organ function. Patient has an ECOG performance status between 0 - 2. Women of childbearing potential should be screened for pregnancy prior to treatment and utilize effective contraceptive methods (e.g. barrier) during treatment period. Patients over the age of 18 who are willing and able to provide Informed Consent The patient has been taking Targretin capsules for at least the last 4 months and the dose has remained relatively stable. The patient has had stable or progressive disease over the past 4 months. Patient has adequate laboratory parameters for liver and kidney function. Exclusion Criteria: Patients with CD30+ Anaplastic Large Cell Lymphoma Patients with pathology consistent with peripheral T-cell lymphoma. Patients with Stage IVB (visceral involvement with CTCL). Patients with history of Human Immunodeficiency Virus (HIV), Hepatitis B or Hepatitis C infection. Patients with a diagnosis of congestive heart failure. Patients exhibiting significant edema or unstable cardiovascular disease. Patients with a fasting triglyceride level greater then 500mg/dl. Patients that have started any new treatment for CTCL in the past 4 months. Pregnant women will be excluded from the study.
Sites / Locations
- Vanderbilt University Medical Center